Nicotine metabolism largely can take location from the liver. Consequently, when nicotine is administered in the GI program, it undergoes to start with-pass metabolism from the liver, resulting in a bioavailability of only about twenty%. This process inherently decreases the bioavailability of nicotine within the program and could result in adverse